Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aequus Pharmaceuticals Inc. (V:AQS)

Business Focus: Pharmaceuticals

Log in or join to add this stock to your watch list.
Jul 29, 2019 08:30 am ET
Aequus Signs Exclusive Distribution Agreement with Medicom Healthcare for Canadian Distribution Rights of Ophthalmic Products
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution agreement with Medicom Healthcare Ltd. (“Medicom”), a United Kingdom based pharmaceutical company...
May 30, 2019 08:00 pm ET
Aequus Provides First Quarter 2019 Financial Highlights
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three...
May 30, 2019 07:30 pm ET
Aequus to Clarify Press Release of 23rd May 2019 Relating to Zepto Capsulotomy System and Kensington Eye Institute
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) confirms its release of 23rd May 2019. Aequus is pleased to be a supplier of the Zepto Capsulotomy System (“the Product”) with the Kensington Eye Institute in...
May 23, 2019 08:45 am ET
Aequus to supply Kensington Eye Institute with Zepto Capsulotomy system; Extends Distribution Agreement with Mynosys
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce an agreement for the Zepto Precision Pulse Capsulotomy device (“Zepto”) with The Kensington Eye Institute, a world renowned clinic and leader...
May 02, 2019 09:15 am ET
Aequus Closes $2.35 Million Offering of Convertible Debenture Units
Aequus Pharmaceuticals Inc. (“Aequus” or the “Company”) (TSX-V: AQS) (OTCQB:AQSZF) is pleased to announce that it has closed its previously announced offering (the “Offering”) of convertible debenture units of the Company (the “Convertible...
Apr 30, 2019 10:00 am ET
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 1, 2019
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief...
Apr 26, 2019 09:16 am ET
Aequus Announces Filing of Prospectus Supplement and an Update to Previously Announced Public Offering of Convertible Debenture Units
Aequus Pharmaceuticals Inc. (the “Company”) (TSX-V: AQS) (OTCQB:AQSZF) is pleased to announce that it has filed a prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017 (the “Base Shelf...
Apr 24, 2019 11:36 pm ET
Aequus Provides Financial Year End Financial Highlights
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the full year...
Apr 03, 2019 10:36 am ET
IIROC Trading Resumption - AQS
VANCOUVER, April 3, 2019 /CNW/ - Trading resumes in:
Apr 03, 2019 10:22 am ET
Aequus Announces Public Offering of Convertible Debenture Units
Aequus Pharmaceuticals Inc. (the “Company”) (TSX-V: AQS) (OTCQB:AQSZF) is pleased to announce that it expects to file a preliminary prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017...
Apr 03, 2019 09:34 am ET
IIROC Trading Halt - AQS
VANCOUVER, April 3, 2019 /CNW/ - The following issues have been halted by IIROC:
Mar 07, 2019 08:30 am ET
Aequus Signs Term Sheet for Five Preservative Free Dry Eye Products
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license with Medicom Healthcare Ltd. (“Medicom”), a United Kingdom based pharmaceutical company...
Dec 17, 2018 08:30 am ET
Aequus Signs Term Sheet with European Partner for a Preservative Free Therapeutic in Ophthalmology  
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European...
Nov 29, 2018 06:15 pm ET
Aequus Reports Largest Quarterly Revenue in Company History and Provides Management Update
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three and...
Nov 15, 2018 08:45 am ET
Aequus Strengthens Clinical Experience on Strategic Advisory Board in Ophthalmology, and Adds Commercial and Regulatory Expertise
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the addition of Dr. Vikram...
Nov 13, 2018 08:45 am ET
Aequus Hosts Live Webinar Demonstrating the Zepto® Capsulotomy System, Led by Dr. Ike Ahmed
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, is pleased to announce the successful presentation...
Nov 05, 2018 08:45 am ET
Aequus forms Strategic Advisory Board in Ophthalmology, Chaired by Dr. Ike Ahmed
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the formation of a strategic...
Aug 27, 2018 08:45 am ET
Aequus Reports 5th Consecutive Quarter of Revenue Growth
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three...
Aug 10, 2018 08:45 am ET
Aequus Closes Balance of $775,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing,...
Aug 09, 2018 08:45 am ET
Aequus Announces Fully-subscribed $775,000 Equity Financing
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a...
Jul 31, 2018 08:45 am ET
Aequus Announces Closing of $800,000 Equity Financing
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that, further to its news...
Jul 24, 2018 06:00 pm ET
Issuance of Stock Options
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), Aequus is pleased to announce it has granted incentive stock options to Damien King, a new director of the Company for the right to purchase up to an aggregate of...
Jul 23, 2018 08:45 am ET
Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a...
Jul 19, 2018 08:45 am ET
Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”) is pleased to announce a recent expansion of the market opportunity for its reformulated anti-nausea transdermal patch, AQS1303, into the European market. Diclectin®,...
Jul 16, 2018 08:45 am ET
Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce that it has agreed to new terms for its promotional service agreement with Sandoz on PRVistitan™ (“Vistitan”) with improved economics and a...
Jul 13, 2018 08:45 am ET
Aequus Announces New Independent Director to its Board
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that following the completion of its Annual...
Jun 21, 2018 08:45 am ET
Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today an expansion of its relationship with...
Jun 18, 2018 08:45 am ET
Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto® Capsulotomy System (“Zepto”), a precision pulse capsulotomy device, have been...
May 31, 2018 08:45 am ET
Aequus Provides First Quarter 2018 Financial and Corporate Highlights
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the first...
May 16, 2018 08:45 am ET
Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it will be formally launching the Zepto® Precision Pulse Capsulotomy System (“Zepto”) in Canada on June 1, 2018 during the Canadian...
May 03, 2018 08:45 am ET
Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the Company has received...
Apr 27, 2018 09:30 am ET
Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth
VANCOUVER, British Columbia, April 27, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the...
Apr 26, 2018 12:00 pm ET
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018
VANCOUVER, British Columbia, April 26, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and...
Apr 17, 2018 08:45 am ET
Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has issued...
Apr 12, 2018 08:45 am ET
Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio
VANCOUVER, B.C., April 12, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it has entered into a commercial agreement with Mynosys Cellular Devices, an ophthalmology focused medical device company...
Mar 19, 2018 08:45 am ET
Aequus Expands Market in Quebec for Tacrolimus IR
First-to-market generic tacrolimus will be included on Sigma Santé contract as of May 2018, building on continued commercial success of Aequus’ promotional arm
Mar 07, 2018 08:45 am ET
FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch
VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the Company has...
Mar 05, 2018 08:45 am ET
Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
Ehave’s Bioinformatics Platform Technology to Be Used to Evaluate Aequus’ Products in Multiple Neurological Disorders
Mar 05, 2018 08:06 am ET
Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
Ehave's Bioinformatics Platform Technology to Be Used to Evaluate Aequus' Products in Multiple Neurological Disorders
Mar 05, 2018 07:45 am ET
Jan 31, 2018 06:21 pm ET
Aequus Announces Closing of $300,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...
Jan 31, 2018 08:00 am ET
Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced plans to advance its...
Jan 25, 2018 05:27 pm ET
Aequus Announces Change to Proposed $300,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...
Jan 11, 2018 08:30 am ET
Aequus Announces Proposed $300,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...
Jan 11, 2018 05:00 am ET
Jan 11, 2018 05:00 am ET
Dec 08, 2017 08:04 pm ET
Aequus announces the issuance of stock options
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options...
Nov 29, 2017 04:15 pm ET
Aequus Provides Third Quarter 2017 Operational Highlights
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three...
Nov 16, 2017 09:43 am ET
Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent...
Sep 28, 2017 09:30 am ET
Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders
TORONTO, Sept. 28, 2017 /CNW/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company's shareholders, providing an update on corporate developments and business strategy. As outlined in the letter, Ehave has established and is executing on key partnerships that allow the company to generate revenue while demonstrating its utility for mental health researchers, pharmaceutical companies and clinicians, setting Ehave on a strong growth trajectory
Sep 28, 2017 09:30 am ET
Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders
TORONTO, Sept. 28, 2017 /PRNewswire/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced publication of a new CEO letter to the Company's shareholders, providing an update on corporate developments and business strategy. As outlined in the letter, Ehave has established and is executing on key partnerships that allow the company to generate revenue while demonstrating its utility for mental health researchers, pharmaceutical companies and clinicians, setting Ehave on a strong growth tra...
Sep 07, 2017 01:23 pm ET
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced positive results from an initial...
Aug 29, 2017 04:30 pm ET
Aequus Provides Second Quarter 2017 Operational Highlights
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three...
Aug 28, 2017 09:00 am ET
Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB: EHVVF) ("Ehave"), a...
Aug 24, 2017 09:00 am ET
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has received positive...
Aug 16, 2017 02:29 pm ET
Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...
Aug 01, 2017 09:00 am ET
Aequus and Scientus Agree to Terms for a Medical Cannabis Commercial Supply and Product Development Collaboration
Aequus Pharmaceuticals Inc., ("Aequus") (TSX VENTURE: AQS) (OTCQB: AQSZF), a specialty life sciences company focused on providing patients with differentiated and enhanced delivery systems for existing and approved drugs, and Scientus Pharma Inc.,...
Jul 05, 2017 09:00 am ET
Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has received approval...
Jun 15, 2017 09:00 am ET
Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that is has filed a Clinical...
Jun 13, 2017 10:52 am ET
IIROC Trading Resumption - AQS
VANCOUVER, June 13, 2017 /CNW/ - Trading resumes in:
Jun 13, 2017 09:46 am ET
IIROC Trading Halt - AQS
VANCOUVER, June 13, 2017 /CNW/ - The following issues have been halted by IIROC:
Jun 13, 2017 09:00 am ET
Santen and Aequus Enter Into a Commercial Collaboration in Canada
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), today announced that it has entered into an exclusive agreement in Canada with Santen Incorporated, the Canadian Branch ("Santen"), a subsidiary of Santen...
Jun 12, 2017 10:00 pm ET
Aequus Approves Advance Notice Policy
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its board of directors...
Jun 01, 2017 09:00 am ET
Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics
Today Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus") a specialty pharmaceutical company with expertise in drug delivery and clinical development, and the Centre For Drug Research and Development ("CDRD"), Canada's national...
May 30, 2017 12:35 pm ET
Aequus Provides First Quarter 2017 Financial Highlights
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the first...
May 15, 2017 02:35 pm ET
Aequus Validates Need for Improved Delivery Methods of Medical Cannabis
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced results from a medical...
May 01, 2017 03:50 pm ET
Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the full...
Apr 24, 2017 09:30 am ET
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief...
Apr 05, 2017 09:00 am ET
Aequus Launches Medical Cannabis Physician Research in US and Canada
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus") announced today they will fund market research targeting up to 500 physicians across Canada and certain US states to further understand their current prescribing experience and...
Apr 03, 2017 05:30 am ET
Aequus Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), today announced results from its second Proof of Concept study designed to evaluate the pharmacokinetics (PK), safety and tolerability following repeat...
Mar 13, 2017 09:12 am ET
Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the closing today of...
Mar 03, 2017 10:08 am ET
IIROC Trading Resumption - AQS
VANCOUVER, March 3, 2017 /CNW/ - Trading resumes in:
Mar 03, 2017 09:40 am ET
Aequus Announces Upsizing of Previously Announced Bought Deal of Units to $4.5 Million
/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Mar 03, 2017 09:22 am ET
IIROC Trading Halt - AQS
VANCOUVER, March 3, 2017 /CNW/ - The following issues have been halted by IIROC:
Mar 02, 2017 04:28 pm ET
Aequus Announces $3 Million Bought Deal Financing
/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Mar 02, 2017 08:00 am ET
Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research Service Contract with Transdermal Research Pharma Lab ("TRPL") it has entered into a binding term...
Feb 14, 2017 08:00 am ET
Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has completed the...
Feb 01, 2017 09:00 am ET
Aequus Receives Non-Dilutive Funding from the Government of Canada to Support Aripiprazole Patch Development
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), today announced funding of up to CAD$100,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC-IRAP") to support the...
Jan 09, 2017 09:00 am ET
Aequus Initiates Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), announced today that it has received approval from Health Canada to initiate a multi-dose Proof of Concept clinical trial to evaluate the bioavailability and...
Dec 01, 2016 08:00 am ET
Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully...
Nov 30, 2016 08:00 am ET
Aequus Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today provided a corporate update and has...
Nov 17, 2016 09:00 am ET
Aequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that is has entered into a service agreement with Corium International, Inc. (NASDAQ: CORI) for the manufacturing of clinical trial materials...
Oct 17, 2016 09:00 am ET
Aequus Advances Clinical Development of Transdermal Aripiprazole Patch
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that is has filed a Clinical...
Oct 03, 2016 12:37 pm ET
Aequus Partners With Camargo to Support US Regulatory Strategy for Development Programs
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has entered into a...
Sep 29, 2016 08:00 am ET
Aequus Obtains Ontario Provincial Listing for Vistitan(TM)
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully...
Sep 13, 2016 09:19 am ET
Aequus Closes Financing for Gross Proceeds of C$2,743,920
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS)(OTCQB:AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus...
Sep 06, 2016 07:58 am ET
Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS) (OTCQB:AQSZF) (the "Company" or "Aequus") is pleased to announce that it has entered into an...
Aug 30, 2016 08:30 am ET
Aequus Provides Corporate Update on Commercial and Development Programs
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) 2016 YTD Company Highlights: Aequus reported its first commercial revenues in Q1 of 2016 for promotional activities in the Canadian market. Second-quarter 2016 revenues of $118,100 and...
Aug 05, 2016 11:00 am ET
Aequus Announces Advancement of Anti-Nausea Transdermal Extended-Release Patent Application
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has filed an...
Jul 29, 2016 09:57 am ET
Aequus Announces Advancement of Clobazam Transdermal Patent Application
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has filed an...
Jul 22, 2016 05:30 pm ET
Aequus Appoints Ann Fehr as Chief Financial Officer
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or "Company") today announced Ann Fehr is joining the growing specialty pharmaceutical company as its new Chief Financial Officer (CFO) effective July 22, 2016. Ms. Fehr brings...
May 02, 2016 09:00 pm ET
Aequus Announces Stock Option Grant
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today it has granted incentive stock options to employees, consultants and directors of the Company for the right to purchase up to an aggregate of...
Apr 28, 2016 09:23 am ET
Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN(TM) in Canada
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that it has initiated commercial activities for PRVistitan™ (bimatoprost 0.03%, ophthalmic solution) in the Canadian market, which is a...
Apr 26, 2016 11:45 am ET
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference
Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief...